EGFR and glioblastoma: EGFRvIII, a common mutant of EGFR which is continually activated even without ligand binding to the receptor, occurs after the pathogenesis of GBM to change the pattern of tumor growth and increase the intra-tumoral heterogeneity and resistance to targeted therapies (23).